Statoil revises its production target for oil and gas
September 29, 2006 02:38 ET
|
Equinor ASA
Statoil ASA is modifying its target for oil and gas production in 2007 by about 3%. Output in 2006 is expected to be about 3% lower than the earlier prognosis. However, the company forecasts a growth...
Statoil reviderer produksjonsmål for olje og gass
September 29, 2006 02:33 ET
|
Equinor ASA
Statoil ASA reviderer ned sitt mål for olje- og gassproduksjon for 2007 med om lag tre prosent. Produksjonen i 2006 forventes å bli om lag tre prosent lavere enn tidligere prognose. Selskapet...
Basilea Reports Excellent Pivotal Data for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Investigational Antibiotic, at ICAAC
September 29, 2006 01:39 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to demonstrate efficacy in a large clinical trial in patients infected with...
New Data Confirming Broad Spectrum of Basilea's Late-Stage Antifungal, BAL8557, Presented at the ICAAC Conference
September 29, 2006 01:27 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Data presented at ICAAC further support phase III development program scheduled to start by year-end in invasive candida (yeast) and aspergillus...
Novartis announces initiative to improve access to state-of-the-art anti-malarial treatment Coartem®
September 29, 2006 01:15 ET
|
Novartis Pharma AG
Malaria strikes 300 million to 500 million people every year, the biggest killer of children in Africa - every 30 seconds a child in Africa dies of this disease
Average cost per Coartem...
Basilea Reports Excellent Pivotal Data for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Investigational Antibiotic, at ICAAC
September 29, 2006 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, Switzerland, September 29, 2006 - Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to demonstrate efficacy in a large clinical trial in patients infected with staphylococcal...
New Data Confirming Broad Spectrum of Basilea's Late-stage Antifungal, BAL8557, Presented at the ICAAC Conference
September 29, 2006 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, Switzerland, September 29, 2006 - Data presented at ICAAC further support phase III development program scheduled to start by year-end in invasive candida (yeast) and aspergillus (mold)...
Neue Daten an ICAAC bestätigen das breite Wirkspektrum von Basileas Antimykotikum BAL8557 - das Pilzmittel befindet sich in der fortgeschrittenen klinischen Entwicklung
September 29, 2006 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, 29. September, 2006 - Die an der ICAAC präsentierten Ergebnisse bestätigen das Potential des Pilzmittels zur Behandlung von invasiven Candida- (Hefepilz) und Aspergillus- (Schimmelpilz)...
Basilea präsentiert an der ICAAC hervorragende Ergebnisse einer Zulassungsstudie von Ceftobiprol - einem neuen anti-MRSA Breitspektrum-Antibiotikum in der Entwicklung
September 29, 2006 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, 29. September, 2006 - Ceftobiprol ist das erste Breitspektrum-Cephalosporin mit anti-MRSA-Aktivität, dessen Wirksamkeit in einer gross angelegten Studie bei Patienten mit Staphylococcus...
Novartis Announces Initiative to Improve Access to State-of-the-Art Anti-Malarial Treatment Coartem
September 29, 2006 01:10 ET
|
Novartis
-- Malaria strikes 300 million to 500 million people every year, the
biggest killer of children in Africa -- every 30 seconds a child
in Africa dies of this disease
-- Average cost per...
- September 01, 2024 22:30 ET David Barrett ประธานกรรมการบริหารของ EBC Financial Group (UK) Ltd และ EBC Financial Group (Cayman) Limited วิเคราะห์ความผันผวนของตลาดโลก แรงกดดันจากอัตราดอกเบี้ยสูง และกลยุทธ์การลงทุนที่ปลอดภัยในบริบทของการเปลี่ยนแปลงทางเศรษฐกิจในปี 2567
- September 01, 2024 16:26 ET PickleJar Debuts Nationwide Jackson Dean Fan Experience Contest With Big Machine Records